Your session is about to expire
← Back to Search
Chemoimmunotherapy for Neuroblastoma
Study Summary
This trial is testing whether adding the drug Hu3F8 to standard chemotherapy drugs irinotecan and temozolomide can help treat cancer with fewer side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the aggregate count of participants enrolled in this clinical trial?
"This clinical research has stopped actively recruiting. The study was posted on June 12th, 2017 and last updated October 19th 2022. Currently there are 162 trials accepting patients with neuroblastoma and 445 studies admitting participants for Hu3F8 therapy."
Are there precedents of research with Hu3F8?
"At the present moment, 445 active clinical trials are researching Hu3F8 with 75 at Phase 3. Of these studies, a majority is being conducted in Adelaide of South Australia; nevertheless, 12811 separate locations around the world have access to this medication for trial purposes."
Are individuals currently being enrolled in this trial?
"This clinical trial has now ceased its search for new candidates, with the original advertisement posted on June 12th 2017 and last updated October 19th 2022. However, 162 other trials are actively recruiting patients diagnosed with neuroblastoma and 445 studies are still accepting participants for Hu3F8 therapy."
What is the typical purpose for administering Hu3F8?
"Hu3F8 is frequently used to manage progression, disease. This immunotherapy can also provide therapeutic benefits for colorectal carcinoma, ovarian cancer, and other maladies such as advance directives."
Share this study with friends
Copy Link
Messenger